RBC flags AstraZeneca-Daiichi lung-cancer drug data as promising
RBC Capital Markets said AstraZeneca and Daiichi Sankyo’s Enhertu showed strong late-stage lung-cancer results, but noted competition ahead in a research note.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.